REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
347.86
+7.40 (+2.17%)
As of 2:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close340.46
Open340.38
Bid345.23 x 800
Ask345.46 x 800
Day's Range337.81 - 347.86
52 Week Range281.89 - 442.00
Volume399,004
Avg. Volume743,964
Market Cap37.849B
Beta (3Y Monthly)1.13
PE Ratio (TTM)16.34
EPS (TTM)21.29
Earnings DateMay 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est428.62
Trade prices are not sourced from all markets
  • Why Investors Should Buy the Dip in MRK Stock
    InvestorPlace23 hours ago

    Why Investors Should Buy the Dip in MRK Stock

    The collapse of healthcare stocks, especially drug companies, may have finally abated. Merck (NYSE:MRK) has fallen 12% from its April 3 high. But the MRK freefall seems to have finally leveled off.Source: Shutterstock The instinctive reaction would be to buy the dip. Merck's five-year gain is now half that of the average S&P 500 stock, but it's still up 24% in the last year. And what initially sent MRK stock down was fear of politicians, not changes at the business.But Merck stock is still not cheap. Its trailing P/E ratio is 32, and the dividend of 55 cents per share still yields just 2.65% -- lower than many other dividend stocks. That dividend was just hiked in December, and thus isn't due to rise again for 8 more months.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Red-Hot E-Commerce Stocks to Consider Merck is due to report first-quarter earnings on April 30, with $1.05 per share expected on revenue of $10.36 billion. That's a big jump from last year's earnings pace, albeit on less revenue. But if MRK stock keeps growing like this, it would justify both a big dividend hike and an increase in its stock buyback, now at $10 billion on a market cap of $192 billion. The Keytruda MiracleThere are also reasons to find the earnings momentum sustainable.Keytruda, a cancer drug best known for having kept former President Jimmy Carter alive a few years ago, continues to score big with regulators. It's now a first-line drug against advanced kidney cancer, in conjunction with Inlyta from Pfizer (NYSE:PFE).Keytruda is one of three so-called PD-1 inhibitors on the market, alongside Opdivo from Bristol-Myers Squibb (NYSE:BMY) and Libtayo from Regeneron (NASDAQ:REGN). These are monoclonal antibodies that keep cells from attacking one another. Turning off this chemical "off switch" boosts the immune system response to cancer cells. While Opdivo is heavily advertised, it is Keytruda that has been scoring the bigger wins in late-stage studies. The most recent one is Keynote-426, which gave 861 patients two years of the drug, which can cost over $100,000 per year. Keytruda was worth over $7 billion to Merck last year. The Price BacklashIt's Keytruda's price, which doesn't apply in countries that bargain directly for drugs, that caused the healthcare sector's fall from grace this month.That pushback takes many forms, from cost-effectiveness studies to state and national legislation. But the industry's lobbyists still stand strong in Republican Washington.This includes Merck CEO Ken Frazier, who recently agreed to stay on past his normal retirement age for a $20.9 million pay package.Frazier is charged with defending the industry against attacks on its profits and diversifying the company's $42 billion in sales beyond Keytruda, which represents 17% of Merck's total revenue.Merck recently won approval for Mavenclad, a potential blockbuster drug for multiple sclerosis, and it made 60 acquisitions during 2018. These include expansion in animal pharmaceuticals and immunotherapy. Its current late-stage drug pipeline has been valued at $13 billion. The Bottom LineMerck is due to bounce back at least 10%, as the recent downdraft in health care stocks fades from memory, just as the December fall of tech stocks faded.Of 18 analysts now following the stock, 13 now have it on their buy lists and confidence is up over three months ago. * 10 Stocks to Sell Before They Give Back 2019 Gains A beat on the quarterly earnings estimate should be the catalyst to take Merck to new highs, and its pipeline should keep it profitable no matter what Congress decides to do. This is a dip both speculators and investors will enjoy buying.Dana Blankenhorn http://www.danablankenhorn.com is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family https://www.amazon.com/Reluctant-Detective-Finds-Her-Family-ebook/dp/B07FSRDR4Y/, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post Why Investors Should Buy the Dip in MRK Stock appeared first on InvestorPlace.

  • TheStreet.com3 days ago

    How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19)

    No matter how old you are, no matter how wealthy you are, you should really have some money socked away in the stock market, Jim Cramer told his Mad Money viewers Monday, as he dedicated the entire show to generational investing, or how to handle your finances at every age. Cramer said the stock market is still the best ladder we have for social mobility. Not all investments are created equal, Cramer told viewers.

  • This Is Why You Shouldn’t Count Regeneron Stock Out
    InvestorPlace3 days ago

    This Is Why You Shouldn’t Count Regeneron Stock Out

    For many healthcare stocks, April 2019 has been like tech's December 2018. Just 19% of healthcare issues are above their 50-day moving averages. Blame presidential candidate Bernie Sanders. Or blame the Democratic House, which has been holding hearings on a variety of ideas for cutting drug costs. Congress may end the practice of patent "gaming," in which drug companies make small tweaks to drugs in order to extend patent protection.Source: Shutterstock But whatever Congress does, it shouldn't impact Regeneron Pharmaceuticals (NASDAQ:REGN) to the degree it has -- Regeneron stock has plunged nearly 20% from over $400 per share on April 9 to an April 22 opening price of $333. Regeneron's MethodI have long been a fan of Regeneron stock. While most drug companies tie their futures to specific cures, Regeneron has always been focused on their methods for finding drugs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThese include Velocisuite, which offers fast manipulation of mouse DNA, and TRAP, a general method for developing enzyme blockers. Methods mean Regeneron's pipeline can be constantly renewed for a variety of conditions, from cancer to pulmonary disease to chronic pain.Methods matter. Methods get companies ahead of trends.Regeneron doesn't just know this in its research strategy but in its investment strategy. This is evidenced by a recent $800 million deal with Alnylam (NASDAQ:ALNY) to work on RNA interference, controlling how genes are expressed by interfering with messenger RNA that turns DNA sequences into traits.If Alnylam were Regeneron's only big bet, I wouldn't be listening to bullish forecasts about it. But it's not. Regeneron has development deals with many other companies, including Sanofi (NASDAQ:SNY) and Bluebird (NASDAQ:BLUE), because its gene manipulation methodology can bring drugs to markets faster. * 10 High-Yielding Dividend Stocks That Won't Wilt By having a drug development methodology and cash to spend with companies with specific therapies in mind, Regeneron investors get the ability to spread their bet across many therapies and approaches. Drugs Out of FashionUnfortunately, that's not how Regeneron is valued. Instead, analysts follow the fate of specific Regeneron cures in the market, acting like competition for a single "blockbuster" is going to sink REGN stock.Right now, this makes REGN stock a great bargain. Regeneron's return on equity is 28%. Its price-to-earnings ratio is below 16, with investors paying $333 for over $21 per share of earnings. That's bargain territory.Regeneron is expected to earn $5.39 per share on revenues of $1.72 billion when it next reports May 7, but it has lately made a habit of beating earnings estimates, often by a lot. Analysts are whispering it might beat estimates this quarter by 14 cents, but in the last quarter, it beat estimates by $1.24, and the current estimates are lower. The Bottom Line on Regeneron StockI take a long-term view on stocks, looking for the leading edge of technology, where the value added to society is greatest.The current decade has been all about the cloud, which has brought enormous amounts of computing power to desktops and even mobile platforms.The next decade will be about using this power to turn DNA into a computer language that can be read and manipulated. A research methodology can act like an old-style PC operating system in this worldThis is not a guarantee of long-term success. It only means a company is playing the new game in the right way. That's what I like about Regeneron stock. It has method amid the madness.Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in REGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post This Is Why You Shouldn't Count Regeneron Stock Out appeared first on InvestorPlace.

  • TheStreet.com3 days ago

    A Bullish Play on Netflix

    Just because we still have a higher bigger-picture target, does not mean that it will definitely make it there, but we do watch targets, since they do get met often enough to make them worth watching. The weekly target in this case comes in at the $475 area. This is a target off the December 2018 low.

  • Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
    Zacks9 days ago

    Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

    Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

  • Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
    Simply Wall St.9 days ago

    Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

    How far off is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and disco...

  • Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
    Zacks9 days ago

    Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

    The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

  • Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
    Zacks10 days ago

    Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

    Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

  • TheStreet.com10 days ago

    Stalking an Entry in Regeneron Pharmaceuticals

    It's because we can make a case for a bigger-picture bullish trend with a different pattern of higher highs and lows. What's most important in my opinion, is whether you have a setup for a market entry.

  • 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
    Zacks14 days ago

    4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

    We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

  • Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
    Zacks15 days ago

    Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

    Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding REGN is favorable, with net inflows of $140.23 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
    Zacks16 days ago

    Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

    Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

  • PR Newswire17 days ago

    Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019

    TARRYTOWN, N.Y. , April 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2019 financial and operating results on Tuesday, May ...

  • Benzinga17 days ago

    Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics

    In a biotech tie-up, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration agreement Monday with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Regeneron and Alnylam said they will exclusively collaborate on discovering, developing and commercializing new RNA interface — or RNAi — therapeutics for a broad range of disease targets expressed in the eye and central nervous system. The companies will also work on therapies for a select number of targets expressed in the liver. The agreement has Regeneron paying $400 million upfront to Alnylam and buying up to $400 million worth of Alnylam stock at $90 per share.

  • Reuters17 days ago

    Regeneron forays into gene-silencing therapies with Alnylam tie-up

    Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology. Alnylam, which last year won U.S. approval for the first treatment using the Nobel prize-winning technology, has a host of other such therapies in its pipeline for various genetic, cardio-metabolic, liver and eye and central nervous system (CNS) diseases. Regeneron will make a $400 million upfront payment to Alnylam and also purchase 4.44 million of Alnylam common shares at $90 per share.

  • Alnylam trades partner Sanofi for Regeneron in $800M deal
    American City Business Journals17 days ago

    Alnylam trades partner Sanofi for Regeneron in $800M deal

    Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.

  • Business Wire17 days ago

    Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc. (REGN), announced today a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments.

  • PR Newswire17 days ago

    Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Regeneron Pharmaceuticals, Inc. (REGN) and Alnylam Pharmaceuticals, Inc. (ALNY) today announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases.

  • Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
    Zacks21 days ago

    Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

    Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.

  • Allergan's AMD Drug Lowers Inflammation in Phase III Study
    Zacks22 days ago

    Allergan's AMD Drug Lowers Inflammation in Phase III Study

    Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

  • Inovio Closes Enrollment in Brain Cancer Study Before Time
    Zacks23 days ago

    Inovio Closes Enrollment in Brain Cancer Study Before Time

    Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

  • Analysts Raise Their Target Price for Regeneron in March
    Market Realist27 days ago

    Analysts Raise Their Target Price for Regeneron in March

    Analysts Are Feeling Good about These Biotech Stocks in MarchAnalysts’ recommendations and target priceWall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals (REGN) based on the company’s closing price on March 27.

  • Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy?
    Insider Monkey28 days ago

    Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Financial Strength Analysis
    Simply Wall St.29 days ago

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Financial Strength Analysis

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Investors looking for stocks with high market liquidity and little debt on the balance sheet should consider Regeneron Phar...